Frontiers in Oncology (Nov 2022)

Identification of a naturally-occurring canine model for early detection and intervention research in high grade urothelial carcinoma

  • Deepika Dhawan,
  • José A. Ramos-Vara,
  • José A. Ramos-Vara,
  • Sagar M. Utturkar,
  • Audrey Ruple,
  • Audrey Ruple,
  • Sarah A. Tersey,
  • Jennifer B. Nelson,
  • Bruce R. Cooper,
  • Hock Gan Heng,
  • Elaine A. Ostrander,
  • Heidi G. Parker,
  • Noah M. Hahn,
  • Larry G. Adams,
  • Christopher M. Fulkerson,
  • Christopher M. Fulkerson,
  • Michael O. Childress,
  • Michael O. Childress,
  • Patty L. Bonney,
  • Christine Royce,
  • Lindsey M. Fourez,
  • Alexander W. Enstrom,
  • Lisbeth A. Ambrosius,
  • Deborah W. Knapp,
  • Deborah W. Knapp

DOI
https://doi.org/10.3389/fonc.2022.1011969
Journal volume & issue
Vol. 12

Abstract

Read online

BackgroundEarly detection and intervention research is expected to improve the outcomes for patients with high grade muscle invasive urothelial carcinoma (InvUC). With limited patients in suitable high-risk study cohorts, relevant animal model research is critical. Experimental animal models often fail to adequately represent human cancer. The purpose of this study was to determine the suitability of dogs with high breed-associated risk for naturally-occurring InvUC to serve as relevant models for early detection and intervention research. The feasibility of screening and early intervention, and similarities and differences between canine and human tumors, and early and later canine tumors were determined.MethodsSTs (n=120) ≥ 6 years old with no outward evidence of urinary disease were screened at 6-month intervals for 3 years with physical exam, ultrasonography, and urinalysis with sediment exam. Cystoscopic biopsy was performed in dogs with positive screening tests. The pathological, clinical, and molecular characteristics of the “early” cancer detected by screening were determined. Transcriptomic signatures were compared between the early tumors and published findings in human InvUC, and to more advanced “later” canine tumors from STs who had the typical presentation of hematuria and urinary dysfunction. An early intervention trial of an oral cyclooxygenase inhibitor, deracoxib, was conducted in dogs with cancer detected through screening.ResultsBiopsy-confirmed bladder cancer was detected in 32 (27%) of 120 STs including InvUC (n=29, three starting as dysplasia), grade 1 noninvasive cancer (n=2), and carcinoma in situ (n=1). Transcriptomic signatures including druggable targets such as EGFR and the PI3K-AKT-mTOR pathway, were very similar between canine and human InvUC, especially within luminal and basal molecular subtypes. Marked transcriptomic differences were noted between early and later canine tumors, particularly within luminal subtype tumors. The deracoxib remission rate (42% CR+PR) compared very favorably to that with single-agent cyclooxygenase inhibitors in more advanced canine InvUC (17-25%), supporting the value of early intervention.ConclusionsThe study defined a novel naturally-occurring animal model to complement experimental models for early detection and intervention research in InvUC. Research incorporating the canine model is expected to lead to improved outcomes for humans, as well as pet dogs, facing bladder cancer.

Keywords